Abstract
Development of a Plasmodium falciparum (Pf) transmission blocking vaccine (TBV) has the potential to significantly impact malaria control. Antibodies elicited against sexual stage proteins in the human bloodstream are taken up with the blood meal of the mosquitoes and inactivate parasite development in the mosquito. In a phase 1 trial, a leading TBV identified as Pfs25-EPA/Alhydrogel® appeared safe and immunogenic, however, the level of Pfs25-specific antibodies were likely too low for an effective vaccine. Pfs230, a 230-kDa sexual stage protein expressed in gametocytes is an alternative vaccine candidate. A unique 6-cysteine-rich domain structure within Pfs230 have thwarted its recombinant expression and characterization for clinical evaluation for nearly a quarter of a century. Here, we report on the identification, biochemical, biophysical, and immunological characterization of recombinant Pfs230 domains. Rabbit antibodies generated against recombinant Pfs230 domains blocked mosquito transmission of a laboratory strain and two field isolates using an ex vivo assay. A planned clinical trial of the Pfs230 vaccine is a significant step toward the potential development of a transmission blocking vaccine to eliminate malaria.
Highlights
Development of a malaria vaccine that effectively protects against parasite infection of both the natural host, Anopheles mosquitoes, and its secondary host, man, would effectively disrupt transmission and clinical disease
We evaluated the minor allelic frequency (MAF) of amino acid substitutions in over 2000 primary sequences for Pfs230D1 reported in the MalariaGen P. falciparum database (28), which represents a large geographical distribution of P. falciparum malaria
The limitation was due to an inability to produce a recombinant form of Pfs230 with the necessary purity, quantity, and quality characteristics required for human studies
Summary
Development of a malaria vaccine that effectively protects against parasite infection of both the natural host, Anopheles mosquitoes, and its secondary host, man, would effectively disrupt transmission and clinical disease. The most well known investigational vaccine against Plasmodium falciparum malaria that recently received a positive scientific opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2015, is identified as RTS,S (MosquirixTM). This vaccine targets the circumsporozoite protein that is present on the surface of the sporozoite, the parasite stage that infects man (1). Efforts toward development of a vaccine to disrupt parasite infection of the mosquito host, identified as a transmission blocking vaccine have to date only been able to evaluate a sexual stage-specific protein, Pfs which is a 25-kDa protein expressed on the zygote and ookinete surfaces. Recombinant Pfs230D1M is a promising component of a transmission blocking vaccine
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have